{"protocolSection":{"identificationModule":{"nctId":"NCT00263042","orgStudyIdInfo":{"id":"EFC5826"},"secondaryIdInfos":[{"id":"2005-002942-20","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes","officialTitle":"Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors","acronym":"CRESCENDO"},"statusModule":{"statusVerifiedDate":"2016-04","overallStatus":"TERMINATED","whyStopped":"Company decision taken in light of demands by certain national health authorities","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-12"},"primaryCompletionDateStruct":{"date":"2009-04","type":"ACTUAL"},"completionDateStruct":{"date":"2009-04","type":"ACTUAL"},"studyFirstSubmitDate":"2005-12-06","studyFirstSubmitQcDate":"2005-12-06","studyFirstPostDateStruct":{"date":"2005-12-07","type":"ESTIMATED"},"dispFirstSubmitDate":"2016-04-21","dispFirstSubmitQcDate":"2016-04-21","dispFirstPostDateStruct":{"date":"2016-05-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-04-21","lastUpdatePostDateStruct":{"date":"2016-05-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.\n\nThe secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.","detailedDescription":"The estimated study duration per patient is 36 to 53 months. All patients will be followed from randomization until a common study end date, which will occur when the last patient has been followed for 33 months."},"conditionsModule":{"conditions":["Cardiovascular Disease"],"keywords":["Myocardial infarction","cerebrovascular accident","obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":18695,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rimonabant","type":"EXPERIMENTAL","description":"Rimonabant 20 mg once daily","interventionNames":["Drug: Rimonabant"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo (for Rimonabant) once daily.","interventionNames":["Drug: Placebo (for Rimonabant)"]}],"interventions":[{"type":"DRUG","name":"Rimonabant","description":"Tablet, oral administration","armGroupLabels":["Rimonabant"],"otherNames":["SR141716","Acomplia"]},{"type":"DRUG","name":"Placebo (for Rimonabant)","description":"Tablet, oral administration","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"First occurrence of any of myocardial infarction, stroke or cardiovascular (CV) death","timeFrame":"From randomization up to common study end date (33-50 months)"}],"secondaryOutcomes":[{"measure":"First occurrence of any of myocardial infarction, stroke, CV death, and CV hospitalization","timeFrame":"From randomization up to common study end date (33-50 months)"},{"measure":"All-cause mortality","timeFrame":"From randomization up to common study end date (33-50 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nWaist circumference \\>102 cm (40 inches) males, \\>88 cm (35 inches) females, with one coronary heart disease (CHD) equivalent or two major risk factors for cardiovascular disease.\n\n* CHD equivalents:\n\n  * Recent (within 3 years)documented heart attack\n  * Documented symptomatic coronary artery disease\n  * Recent (within 3 years) ischemic cerebrovascular episode (stroke or TIA)\n  * Documented symptomatic peripheral arterial disease\n* Major risk factors:\n\n  * Documented type 2 diabetes mellitus\n  * Metabolic syndrome (NCEP criteria)\n  * Asymptomatic cerebrovascular, renal, or peripheral arterial disease, or past abdominal aortic aneurysm repair\n  * Elevated high-sensitivity C-reactive protein\n  * Age \\> or = 65 years for males, age \\> or = 70 years for females\n\nExclusion Criteria:\n\n* Obesity of known endocrine origin\n* Pregnant or breastfeeding women\n* Very low calorie diet or weight loss surgery within past 6 months\n* Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation, including uncontrolled serious psychiatric illness\n* Likely cardiovascular intervention within next 1 month\n* Allergy to rimonabant or excipients, or prior participation in a rimonabant trial\n* Receipt of investigational product within past 30 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Eric Topol, MD","affiliation":"Scripps Clinic","role":"STUDY_CHAIR"},{"name":"Deepak L. Bhatt, MD","affiliation":"The Cleveland Clinic","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Sanofi-Aventis Administrative Office","city":"Bridgewater","state":"New Jersey","zip":"08807","country":"United States","geoPoint":{"lat":40.60079,"lon":-74.64815}},{"facility":"Sanofi-Aventis Administrative Office","city":"Buenos Aires","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"sanofi-aventis Australia & New Zealand administrative office","city":"Macquarie Park","state":"New South Wales","country":"Australia","geoPoint":{"lat":-33.7751,"lon":151.11272}},{"facility":"Sanofi-Aventis Administrative Office","city":"Vienna","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Sanofi-Aventis Administrative Office","city":"Diegem","country":"Belgium","geoPoint":{"lat":50.89727,"lon":4.43354}},{"facility":"Sanofi-Aventis Administrative Office","city":"Sao Paulo","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Sanofi-Aventis Administrative Office","city":"Laval","state":"Quebec","country":"Canada","geoPoint":{"lat":45.56995,"lon":-73.692}},{"facility":"Sanofi-Aventis Administrative Office","city":"Santiago de Chile","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Sanofi-Aventis Administrative Office","city":"Shanga√Ø","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Sanofi-Aventis Administrative Office","city":"Santafe de Bogota","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"Sanofi-Aventis Administrative Office","city":"Praha","country":"Czech Republic","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Sanofi-Aventis Administrative Office","city":"Horsholm","country":"Denmark","geoPoint":{"lat":55.88098,"lon":12.50111}},{"facility":"Sanofi-Aventis Administrative Office","city":"Helsinki","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Sanofi-Aventis Administrative Office","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Sanofi-Aventis Administrative Office","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Sanofi-Aventis Administrative Office","city":"Athens","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Sanofi-Aventis Administrative Office","city":"Hong-Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Sanofi-Aventis Administrative Office","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Sanofi-Aventis Administrative Office","city":"Mumbai","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Sanofi-Aventis Administrative Office","city":"Dublin","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Sanofi-Aventis Administrative Office","city":"Natanya","country":"Israel"},{"facility":"Sanofi-Aventis Administrative Office","city":"Milano","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Sanofi-Aventis Administrative Office","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Sanofi-Aventis Administrative Office","city":"Kuala Lumpur","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Sanofi-Aventis Administrative Office","city":"Mexico","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Sanofi-Aventis Administrative Office","city":"Gouda","country":"Netherlands","geoPoint":{"lat":52.01667,"lon":4.70833}},{"facility":"Sanofi-Aventis Administrative Office","city":"Lysaker","country":"Norway","geoPoint":{"lat":59.90994,"lon":10.63545}},{"facility":"Sanofi-Aventis Administrative Office","city":"Lima","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Sanofi-Aventis Administrative Office","city":"Makati City","country":"Philippines","geoPoint":{"lat":14.55027,"lon":121.03269}},{"facility":"Sanofi-Aventis Administrative Office","city":"Warszawa","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Sanofi-Aventis Administrative Office","city":"Porto Salvo","country":"Portugal","geoPoint":{"lat":38.71745,"lon":-9.29833}},{"facility":"Sanofi-Aventis Administrative Office","city":"Bucuresti","country":"Romania","geoPoint":{"lat":44.42802,"lon":26.09665}},{"facility":"Sanofi-Aventis Administrative Office","city":"Moscow","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Sanofi-Aventis Administrative Office","city":"Singapore","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Sanofi-Aventis Administrative Office","city":"Midrand","country":"South Africa","geoPoint":{"lat":-25.98953,"lon":28.12843}},{"facility":"Sanofi-Aventis Administrative Office","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Sanofi-Aventis Administrative Office","city":"Bromma","country":"Sweden","geoPoint":{"lat":59.34,"lon":17.94}},{"facility":"Sanofi-Aventis Administrative Office","city":"Geneva","country":"Switzerland","geoPoint":{"lat":46.20222,"lon":6.14569}},{"facility":"Sanofi-Aventis Administrative Office","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Sanofi-Aventis Administrative Office","city":"Bangkok","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Sanofi-Aventis Administrative Office","city":"Megrine","country":"Tunisia","geoPoint":{"lat":36.76917,"lon":10.23639}},{"facility":"Sanofi-Aventis Administrative Office","city":"Istanbul","country":"Turkey","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Sanofi-Aventis Administrative Office","city":"Guildford","country":"United Kingdom","geoPoint":{"lat":51.23536,"lon":-0.57427}}]},"referencesModule":{"references":[{"pmid":"20709233","type":"RESULT","citation":"Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X."},{"pmid":"20976246","type":"DERIVED","citation":"Bhatia G, Bansal V, Harismendy O, Schork NJ, Topol EJ, Frazer K, Bafna V. A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol. 2010 Oct 14;6(10):e1000954. doi: 10.1371/journal.pcbi.1000954."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Bulgaria","Croatia"]},"conditionBrowseModule":{"meshes":[{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M12391","name":"Obesity","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11845","name":"Myocardial Infarction","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077285","term":"Rimonabant"}],"ancestors":[{"id":"D000019440","term":"Anti-Obesity Agents"},{"id":"D000063387","term":"Cannabinoid Receptor Antagonists"},{"id":"D000063385","term":"Cannabinoid Receptor Modulators"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000006728","term":"Hormones"},{"id":"D000006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1739","name":"Rimonabant","asFound":"PI3K","relevance":"HIGH"},{"id":"M21086","name":"Anti-Obesity Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M9479","name":"Hormones","relevance":"LOW"},{"id":"M9478","name":"Hormone Antagonists","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnObAg","name":"Anti-Obesity Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}